Posted by Michael Wonder on 06 Feb 2019
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
6 February 2019 - NICE and the Canadian Agency for Drugs and Technology in Health have launched a new collaboration to offer parallel scientific advice to the life sciences industry.
Scientific advice helps companies develop the evidence that can demonstrate the value of a new treatment. It does so by using expert opinion from a range of contributors including clinicians, health economists and patient representatives to provide detailed feedback on companies’ plans to generate clinical and economic evidence.
The two health technology assessment organisations have a lot in common in terms of how they evaluate new treatments and value the opportunity for early engagement with companies targeting the English and Canadian markets. The advice will help companies prepare for future health technology assessments by answering their questions and providing key insight on their clinical and health economic development plans.
